| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 8 months ago) | |
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 2 months ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| US9439901 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
Steglujan is owned by Msd Sub Merck.
Steglujan contains Ertugliflozin; Sitagliptin Phosphate.
Steglujan has a total of 10 drug patents out of which 5 drug patents have expired.
Expired drug patents of Steglujan are:
- US7459428
- US6890898
- US7078381
- US6699871*PED
- US6699871
Steglujan was authorised for market use on 19 December, 2017.
Steglujan is available in tablet;oral dosage forms.
Steglujan can be used as ertugliflozin and sitagliptin in combination as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, ertugliflozin in combination with sitagliptin and in further combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Drug patent challenges can be filed against Steglujan from 19 December, 2021.
The generics of Steglujan are possible to be released after 21 October, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: Ertugliflozin in combination with sitagliptin and in further combination with metformin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Ertuglif...
Dosage: TABLET;ORAL
STEGLUJAN family patents
